ORG Partners LLC Boosts Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

ORG Partners LLC increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 17.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,000 shares of the biotechnology company’s stock after buying an additional 300 shares during the period. ORG Partners LLC’s holdings in Sarepta Therapeutics were worth $243,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in SRPT. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth $4,771,000. Simplify Asset Management Inc. increased its holdings in Sarepta Therapeutics by 84.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after purchasing an additional 88,474 shares during the period. Geode Capital Management LLC increased its holdings in Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC raised its position in Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Finally, Larson Financial Group LLC grew its position in shares of Sarepta Therapeutics by 1,649.8% during the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after buying an additional 8,249 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SRPT. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Thursday, December 19th. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. Needham & Company LLC cut their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research note on Wednesday, November 27th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Trading Down 1.2 %

NASDAQ SRPT opened at $124.79 on Friday. The firm’s fifty day moving average is $122.11 and its two-hundred day moving average is $131.33. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $11.92 billion, a PE ratio of 99.83 and a beta of 0.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.